[
    [
        {
            "time": "",
            "original_text": "探营生物医药“次新股” 药企高管聚焦研发“生命线” 建言优化“再融资”路径",
            "features": {
                "keywords": [
                    "生物医药",
                    "次新股",
                    "药企高管",
                    "研发",
                    "生命线",
                    "再融资"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "探营生物医药“次新股” 药企高管聚焦研发“生命线” 建言优化“再融资”路径",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]